FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2331870538> ?p ?o ?g. }

• W2331870538 endingPage "940" @default.
• W2331870538 startingPage "931" @default.
• W2331870538 abstract "Background Antithrombin III (AT III) treatment has been shown to reduce disseminated intravascular coagulation and to inhibit thrombin, which plays a central role in the activation of platelets and other inflammatory systems in conditions with severe inflammation. The objective of this study was to evaluate the influence of early and high-dose administration of AT III to patients with severe multiple injuries on the inflammatory response and outcome. Methods In a placebo-controlled, double-blind study, 40 consecutive patients with Injury Severity Scores of 29 or greater who met the inclusion criteria were randomized to receive either AT III or placebo within 360 minutes after trauma. Twenty patients were administered AT III for a period of 4 days, aiming to achieve AT III concentrations of 140% of normal. Results The AT III and placebo groups were comparable with respect to Injury Severity Score, age, incidence of blood pressure less than 80 mm Hg on admission, initial base deficit, and start of the test drug. The patients in the AT III group received a total of about 20,000 IU during the first 4 days. AT III levels of 130 to 140% could be achieved by this regimen, whereas in the control group the AT III concentration averaged about 70%. In the AT III group prothrombin tended to be elevated and prothrombin fragment F1 + 2 as well as thrombin-AT III complex tended to be lower on the first day. No differences between groups, however, could be observed with respect to partial thromboplastin time, prothrombin time, platelets, plasminogen activator inhibitor I, soluble tumor necrosis factor receptor II, neutrophil elastase, interleukin (IL)-1 receptor antagonist, IL-6, and IL-8. Mortality (15 vs. 5%), incidence of respiratory failure (55 vs. 55%), duration of mechanical ventilation (13 vs. 12 days), and length of stay in the surgical intensive care unit (19 vs. 21 days) were also similar in both treatment groups. The duration of organ failure, however, was shorter in the patients receiving AT III. Conclusion The early and high-dose administration of AT III to patients with severe blunt trauma appears not to attenuate the posttraumatic inflammatory response or to significantly improve outcome." @default.
• W2331870538 created "2016-06-24" @default.
• W2331870538 creator A5009269095 @default.
• W2331870538 creator A5019959764 @default.
• W2331870538 creator A5035296329 @default.
• W2331870538 creator A5082443199 @default.
• W2331870538 creator A5082556159 @default.
• W2331870538 creator A5085145616 @default.
• W2331870538 creator A5090968966 @default.
• W2331870538 date "1998-11-01" @default.
• W2331870538 modified "2023-09-27" @default.
• W2331870538 title "High-Dose Antithrombin III Treatment of Severely Injured Patients" @default.
• W2331870538 cites W103962634 @default.
• W2331870538 cites W105869727 @default.
• W2331870538 cites W1591408368 @default.
• W2331870538 cites W1964168896 @default.
• W2331870538 cites W1974406014 @default.
• W2331870538 cites W1978533211 @default.
• W2331870538 cites W1981924181 @default.
• W2331870538 cites W1999030808 @default.
• W2331870538 cites W1999644118 @default.
• W2331870538 cites W2002764610 @default.
• W2331870538 cites W2005736107 @default.
• W2331870538 cites W2011500795 @default.
• W2331870538 cites W2018720866 @default.
• W2331870538 cites W2020512448 @default.
• W2331870538 cites W2020694202 @default.
• W2331870538 cites W2030780661 @default.
• W2331870538 cites W2054337092 @default.
• W2331870538 cites W2054839157 @default.
• W2331870538 cites W2056261557 @default.
• W2331870538 cites W2056756157 @default.
• W2331870538 cites W2088778180 @default.
• W2331870538 cites W2101516507 @default.
• W2331870538 cites W2113481864 @default.
• W2331870538 cites W2164729929 @default.
• W2331870538 cites W2170775692 @default.
• W2331870538 cites W2412938120 @default.
• W2331870538 cites W4240100796 @default.
• W2331870538 cites W4293108385 @default.
• W2331870538 doi "https://doi.org/10.1097/00005373-199811000-00015" @default.
• W2331870538 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9820705" @default.
• W2331870538 hasPublicationYear "1998" @default.
• W2331870538 type Work @default.
• W2331870538 sameAs 2331870538 @default.
• W2331870538 citedByCount "47" @default.
• W2331870538 countsByYear W23318705382012 @default.
• W2331870538 countsByYear W23318705382013 @default.
• W2331870538 countsByYear W23318705382014 @default.
• W2331870538 countsByYear W23318705382015 @default.
• W2331870538 countsByYear W23318705382016 @default.
• W2331870538 countsByYear W23318705382021 @default.
• W2331870538 countsByYear W23318705382022 @default.
• W2331870538 countsByYear W23318705382023 @default.
• W2331870538 crossrefType "journal-article" @default.
• W2331870538 hasAuthorship W2331870538A5009269095 @default.
• W2331870538 hasAuthorship W2331870538A5019959764 @default.
• W2331870538 hasAuthorship W2331870538A5035296329 @default.
• W2331870538 hasAuthorship W2331870538A5082443199 @default.
• W2331870538 hasAuthorship W2331870538A5082556159 @default.
• W2331870538 hasAuthorship W2331870538A5085145616 @default.
• W2331870538 hasAuthorship W2331870538A5090968966 @default.
• W2331870538 hasConcept C120665830 @default.
• W2331870538 hasConcept C121332964 @default.
• W2331870538 hasConcept C126322002 @default.
• W2331870538 hasConcept C141071460 @default.
• W2331870538 hasConcept C142724271 @default.
• W2331870538 hasConcept C144594695 @default.
• W2331870538 hasConcept C204787440 @default.
• W2331870538 hasConcept C27081682 @default.
• W2331870538 hasConcept C2777557582 @default.
• W2331870538 hasConcept C2778205648 @default.
• W2331870538 hasConcept C2778261982 @default.
• W2331870538 hasConcept C2778382381 @default.
• W2331870538 hasConcept C2779026020 @default.
• W2331870538 hasConcept C2780434524 @default.
• W2331870538 hasConcept C2781413609 @default.
• W2331870538 hasConcept C42219234 @default.
• W2331870538 hasConcept C61511704 @default.
• W2331870538 hasConcept C71924100 @default.
• W2331870538 hasConcept C89560881 @default.
• W2331870538 hasConcept C90924648 @default.
• W2331870538 hasConceptScore W2331870538C120665830 @default.
• W2331870538 hasConceptScore W2331870538C121332964 @default.
• W2331870538 hasConceptScore W2331870538C126322002 @default.
• W2331870538 hasConceptScore W2331870538C141071460 @default.
• W2331870538 hasConceptScore W2331870538C142724271 @default.
• W2331870538 hasConceptScore W2331870538C144594695 @default.
• W2331870538 hasConceptScore W2331870538C204787440 @default.
• W2331870538 hasConceptScore W2331870538C27081682 @default.
• W2331870538 hasConceptScore W2331870538C2777557582 @default.
• W2331870538 hasConceptScore W2331870538C2778205648 @default.
• W2331870538 hasConceptScore W2331870538C2778261982 @default.
• W2331870538 hasConceptScore W2331870538C2778382381 @default.
• W2331870538 hasConceptScore W2331870538C2779026020 @default.
• W2331870538 hasConceptScore W2331870538C2780434524 @default.
• W2331870538 hasConceptScore W2331870538C2781413609 @default.
• W2331870538 hasConceptScore W2331870538C42219234 @default.

• next